Skip to main content
Premium Trial:

Request an Annual Quote

Molecular Informatics, Genzyme Sign Licensing Agreement for BioMerge

Premium

SANTA FE, NM--Molecular Informatics Inc., a bioinformatics software company here, has signed a deal with Genzyme Corp. to license Molecular Informatics's BioMerge software to enhance and support the Multiple Allele-Specific Diagnostic Assay (MASDA) and Serial Analysis of Gene Expression (SAGE) products offered by two Genzyme subsidiaries.

BioMerge combines object-oriented and relational database technologies in an enterprise-wide software system used to process, manage, integrate, and analyze genomic information. The agreement also gives Genzyme early access to Molecular Informatics technology, consulting, and product services.

MASDA is used to analyze multiple patient DNA samples for hundreds of mutations on one or more genes at the same time. SAGE is a genomics tool that detects and quantitates gene expression levels in different tissues. BioMerge will help compare the genetic data generated by MASDA and SAGE to that in public genomic databases.

Filed under

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.